Guangzhou KingMed Diagnostics Group has established 39 major medical laboratories and 670 rural medical laboratories across China, which carry out pathological analysis and detection, as well as provide related medical services to the public.
The group is located at Guangzhou International Biological Island.
Liang Yaoming, chairman and chief executive officer of KingMed, said his company is now providing medical testing services for more than 23,000 medical institutions, with an annual specimen amount of more than 150 million, covering 90 percent of the Chinese population.
"KingMed is expecting to be able to allow more patients to enjoy medical experts' consultations at home via long-distance diagnosis by expanding its lab network and online platforms to rural counties and townships," Liang said.
KingMed is also focusing on further improving its major and grassroots hospitals' diagnostic level of difficult miscellaneous and rare diseases, he added.
Listed on the Shanghai Stock Exchange, KingMed established its first third-party medical laboratory in Tibet autonomous region last year, offering pathological analysis and testing services to residents.
The lab in Tibet completed the pathological analysis of more than 3,000 samples and helped carry out more than 120 remote digital pathological consultations in the previous year, helping local rural patients enjoy medical consultations from major hospitals, as well as from senior doctors and medical experts from around the country. KingMed has also been setting up a series of inflatable laboratories, known as "falcon cube laboratories," to provide quick and high-quality testing for key groups of people by using advanced technologies in Hong Kong, Guangzhou, Nanjing, Yangzhou, Xiamen, Yinchuan, Lanzhou, Dalian, Manzhouli, and Shaoxing to help local governments in their COVID-19 prevention and control efforts since 2021.
A Guangzhou KingMed Diagnostics Group staff member at work.